A Review on FDA Approval of Lymphoma Drug Ukoniq (Umbralisib) And Its Withdrwal Due to Safety Concerns . Journal of Pharmaceutical Negative Results 2022, 13 (4), 1465-1474. https://doi.org/10.47750/pnr.2022.13.04.206.